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Abstract
Purpose of Review The aim of this study was to examine the synaptic biomarker neurogranin in cerebrospinal fluid (CSF) in
different stages of HIV infection and in relation to what is known about CSF neurogranin in other neurodegenerative diseases.
Recent Findings CSF concentrations of neurogranin are increased in Alzheimer’s disease, but not in other neurodegenerative
disorder such as Parkinson’s disease, frontotemporal dementia, and Lewy body dementia. Adults with HIV-associated dementia
have been found to have decreased levels of neurogranin in the frontal cortex, which at least to some extent, may be mediated by
the proinflammatory cytokines IL-1β and IL-8.
Summary CSF neurogranin concentrations were in the same range for all groups of HIV-infected individuals and uninfected
controls. This either indicates that synaptic injury is not an important part of HIV neuropathogenesis or that CSF neurogranin is
not sensitive to the type of synaptic impairment present in HIV-associated neurocognitive disorders.
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Introduction
Neurogranin is a neuron-specific post-synaptic protein, abun-
dant in excitatory neurons in the cortex, hippocampus, and
amygdala [1]. It plays an important part in synaptic plasticity,
enhancing synaptic strength by regulating the availability of
calmodulin [2, 3]. This process is an essential part in long-
term potentiation (LTP), a process believed to be essential to
generate memories. Neurogranin knock-out mice display loss
of spatial and emotional learning as well as a decrease in LTP
induction resulting in disorientation [4]. In humans, synaptic
dysfunction (assessed via CSF neurogranin) has been associ-
ated with memory performance [5].
Neurogranin can be quantified in CSF with enzyme-linked
immunosorbent assay (ELISA), and it has been studied in
various neurocognitive disorders. Alzheimer’s disease affects
the brain regions where neurogranin is mainly expressed, i.e.,
the hippocampus, amygdala, and the neocortex. Synapse loss
has been shown to be an early event, occurring prior to neu-
ronal death and cognitive decline [6–8]. Neurogranin levels
are markedly reduced in the frontal cortex and hippocampus
in Alzheimer’s disease, indicating loss of post-synaptic
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elements [9]. The development of novel anti-neurogranin
monoclonal antibodies has made it possible to quantify low
levels of neurogranin in CSF [10•]. Several studies have
shown that CSF neurogranin concentrations are elevated in
patients with mild cognitive impairment due to Alzheimer’s
disease as well as in patients with Alzheimer’s disease [10•,
11]. There is a correlation between levels of CSF neurogranin
and the severity of cognitive decline and brain atrophy in early
stages of the disease [12, 13].
Since synapse degeneration occurs in all neurodegenera-
tive processes, it is an unexpected finding that CSF
neurogranin concentrations are not increased in other neuro-
degenerative disorders such as Parkinson’s disease,
frontotemporal dementia, Lewy body dementia, progressive
supranuclear palsy, or multiple system atrophy, indicating that
high CSF neurogranin might be specific for Alzheimer’s dis-
ease [14, 15•]. This could be explained by the fact that the
main brain regions affected by Alzheimer’s disease are also
the regions with the highest expression of neurogranin.
In regard to multiple sclerosis and neuroinflammatory con-
ditions, there is very little published on CSF neurogranin.
Although axonal damage may be pronounced in relapsing-
remitting multiple sclerosis, in one published study, there were
no signs of dendritic spine involvement and CSF neurogranin
levels were normal [16].
Soon after transmission, HIV can be detected in the cere-
brospinal fluid (CSF) in most individuals [17, 18]. If left un-
treated, it will lead to a neurodegenerative process with in-
flammation and neuronal loss that eventually can manifest
with HIV encephalitis presenting as subacute HIV-associated
dementia (HAD) [19, 20]. Since neurons are not infected by
HIV, other mechanisms must be involved in the neuropatho-
logical damage. In addition to neuronal injury and death, syn-
aptic disruption also contributes to neurocognitive impairment
in HIV-infected individuals. The pathogenesis of neurodegen-
eration, including synaptic injury, is still only partially under-
stood, but chronic immune activation and a combination of
secondary effects due to both viral and host factors have been
suggested [21–23].
Several CSF biomarkers reflect the intrathecal immune
activation and neuronal damage in HIV infection.
Neopterin is an important marker of cell-mediated immune
activation. It is mainly produced by activated macro-
phages/monocytes, and its CSF levels increase with in-
creasing immunosuppression in untreated HIV-infected in-
dividuals and are highest in patients with HAD and CNS
opportunistic infections [24, 25]. CSF neurofilament light
protein (NFL) is a sensitive marker of HIV-induced axonal
injury [25, 26, 27•]. CSF NFL concentrations are highest in
individuals with HAD where neuronal damage and loss are
prominent, but some untreated individuals without
neurocognitive symptoms with low CD4+ T cell counts
may also have high levels.
HIVand Alzheimer’s disease share some similar features in
neuropathology. One example is the increased deposition of
hyperphosphorylated tau in the hippocampus [28], but there
are also differences. Green et al. found ß-amyloid plaques in
brains fromHIV-infected individuals [29], whereas others [28,
30] have not detected any difference when compared to HIV-
negative age-matched controls.
There are also similarities as well as differences in CSF
biomarkers between HAD and Alzheimer’s disease. Typical
changes in CSF biomarkers in Alzheimer’s disease include
increases in total tau (t-tau) and phosphorylated tau (p-tau)
and a decrease in Aβ1–42 [31]. In HIV-infected individuals
with neuronal injury and cognitive impairment, t-tau can be
elevated but p-tau is generally not [32–34].
There is a potential for synaptic injury in HIV infection by
exposure to viral proteins such as Tat and gp120 and proin-
flammatory substances released by activated cells in the CNS
[22]. There is, however, only scarce information about the role
or perturbation of neurogranin in HIV infection, and to our
knowledge, nothing about CSF neurogranin levels. In a re-
cently published study, it was found that patients with HIV-
associated neurocognitive disorders had significantly reduced
expression of neurogranin in frontal cortex tissues compared
to uninfected controls [35].
HIV-infected individuals now have long lifespans and there-
fore are at risk of being affected by diseases that come with age,
such as various neurocognitive disorders. It is important to be
able to correctly diagnose these conditions. CSF biomarkers add
valuable information in situations like this, since they can aid in
discriminating between different conditions.
To test the hypothesis that synapses are involved in the
neuropathogenic pathway in HIV-1 infection, we have ana-
lyzed CSF neurogranin in a cohort of HIV-infected individuals
thoroughly classified by systemic progression, CNS symp-
tomatic presentation, and antiretroviral therapy (ART).
Methods
In this cross-sectional study, we used archived CSF samples
from two academic centers: Sahlgrenska University Hospital,
Gothenburg, Sweden, and San Francisco General Hospital,
University of California San Francisco (UCSF), USA. All
research protocols and informed consents were reviewed and
approved by an ethics committee.
The study consisted of 138 HIV-infected individuals divided
into six groups and 13 HIV-negative controls. HIV-infected par-
ticipants were divided into four groups with untreated subjects
without neurological impairment (neuroasymptomatic; NA)
stratified by CD4+ T cell count into CD4 < 50 cells/μL (n =
25), CD4 50–199 cells/μL (n = 25), CD4 200–349 cells/μL
(n= 25), and CD4 > 350 cells/μL (n= 30), subjects with HAD
(n= 11), and subjects on suppressive ARTwithout signs of neu-
rological impairment (n = 33).
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CSF Samples and Analytical Methods
Cell counts, HIV RNA, and proteins were analyzed immedi-
ately after sampling and remaining aliquots were centrifuged
and frozen at − 70 °C until further analysis.
CSF neurogranin was measured by an in-house ELISA using
Ng7 as capturing antibody and polyclonal Ng anti-rabbit antibody
(ab23570; Upstate Biotechnology, Lake Placid, NY, USA) as de-
tecting antibody, as previously described in detail [11]. All samples
were analyzed in one round of experiments using one batch of
reagents by board-certified laboratory technicians who were
blinded to clinical data. The lower limit of quantification was
125 pg/mL, and intra-assay coefficients of variation were below
10%. CSF NFL was measured using a commercially available
sandwich ELISA (NF-light® ELISA kit, UmanDiagnostics AB,
Umeå, Sweden). Upper reference values are age-dependent [27•].
CSF neopterin was analyzed using a commercially available im-
munoassay (BRAHMS, Berlin, Germany) with an upper normal
reference value of 5.8 nmol/L [24].
HIV RNA in CSF and plasma was measured using the
Roche Amplicor Monitor version 1.5, Roche Taqman assay
version 1 or 2 (Hoffman La-Roche, Basel, Switzerland), or
Abbott RealTime HIV-1 assay (Abbott Laboratories; Abbott
Park, Illinois, USA). Lower limit of detection was 20–40
copies/mL.
Statistical Methods
Statistical analysis was made with SPSS version 21 (IBM for
Mac) and graphs made by GraphPad, Prism 7.0. Correlations
were analyzed by Pearson correlation analysis. One-way
ANOVA with Tukey’s multiple comparisons tests were used
for adjusted p values for differences between groups. To re-
duce skewness, the following parameters were log trans-
formed: plasma HIV RNA, CSF HIV RNA, CSF NFL, CSF
neopterin, CSF neurogranin, and CD4+ T cell count.
Results
Patient characteristics are presented in Table 1. In contrast to CSF
NFL, there were no significant differences in CSF neurogranin
levels between any of the studied groups; although, there was a
relatively wide range within each group (Fig. 1a). CSF
neurogranin concentrations were in the same range for HIV-
negative controls as all groups of HIV-infected individuals.
CSF NFL concentrations were highest in the HAD group and
significantly higher CSF NFL was also found in
neuroasymptomatic individuals with low CD4+ T cell counts as
compared to those with higher CD4+ T cell counts and HIV-
nega t ive con t ro l s . Pa r t i c ipan t s wi th HAD and
neuroasymtpomatic individuals with low CD4+ counts also had
higher CSF neopterin and NFL levels compared with the other
groups (Fig. 1b, c). Aweak but statistically significant correlation
was found between CSF neurogranin and CSF NFL concentra-
tions (r = 0.38, p < 0.0001) (Fig. 2). The correlation between
CSF neurogranin and CSF neopterin was even weaker, but still
significant (r= 0.18, p< 0.05), but stronger between CSF NFL
and CSF neopterin (r = 0.47, p < 0.0001).
Discussion
The pathogenesis leading to neuronal injury and death in HIV-
infection is complex and far from completely understood. Our
aim was to investigate if early synaptic dysfunction could pre-
cede axonal injury in HIV-infected individuals, but CSF
neurogranin concentrations were in the same range for all partic-
ipants, uninfected controls, individuals with CD4+ T cell counts
ranging from less than 50 to more than 349, individuals on sup-
pressive ART, and even individuals with HAD. This either indi-
cates that synaptic injury is not an important part of HIV patho-
genesis in the CNS or, which probably is more likely, that CSF
neurogranin is not a sensitive marker for the type of synaptic
Table 1 Patient characteristics
N Age (years) Gender (female) CD4 (cells/μL) Plasma HIV RNA
Group Median (IQR) Number (%) Median (IQR) Log10 copies/mL
HIV negative 13 39 (29–47) 3 (23) 702* N.A
HIV neuroasymptomatic
CD4 > 350 30 41 (32–45) 10 (33) 462 (397–618) 4.17 (3.72–4.57)
CD4 200–349 25 39 (32–48) 9 (36) 240 (220–290 4.74 (4.32–5.04)
CD4 50–199 25 42 (34–51) 13 (52) 110 (90–139) 5.09 (4.66–5.42)
CD4 < 50 25 44 (36–48) 9 (36) 20 (10–30) 5.49 (5.00–5.90)
HIV-associated dementia 11 43 (40–57) 0 (0) 60 (39–137) 5.69 (5.46–5.82)
Neuroasymptomatic, ART 33 44 (36–54) 13 (39) 580 (450–830) < 1.30 (< 1.30–< 1.30)
N number, IQR interquartile range, NA not analyzed, ART antiretroviral therapy, CSF cerebrospinal fluid
*CD4 only available for four controls, IQR not presented
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impairment that may be ongoing in HIV-associated
neurocognitive disorders, in analogy with several other neurode-
generative disorders [15•].
A study published earlier this year found that individuals
with HAD had significantly lower expression of neurogranin
in tissue from frontal cortex [35]. CSF neurogranin concentra-
tions were not evaluated. The number of participants with
HAD was, however, very low (n = 3), and even though they
were on ART, they had high plasma viral loads, so the results
need to be interpreted with caution.
In Alzheimer’s disease, there is also a marked reduction of
neurogranin levels in frontal cortex and hippocampus, the
same areas of the brain where neurogranin is mostly
expressed. CSF neurogranin levels are increased in
Alzheimer’s disease, but not in other studied neurodegenera-
tive disorders [15•]. When quantified with the samemethod as
in this study, individuals with Alzheimer’s disease had signif-
icantly higher CSF neurogranin levels than the other groups
(median and interquartile range), 463 (275–669) pg/mL in
Alzheimer’s disease, compared with 196 (120–297) pg/mL
in healthy controls, 120 (120–304) pg/mL in Lewy body
dementia, 156 (120–283) pg/mL in Parkinson’s disease, 188
(120–302) pg/mL) in progressive supranuclear palsy, and 191
(120–265) in multiple system atrophy. This could perhaps be
due to the fact that different brain regions are affected by
various disorders or that the degree of synaptic injury, and
hence, neurogranin levels in CSF vary. It has therefore been
suggested that CSF neurogranin could be used as a specific
biomarker for Alzheimer’s disease.
With an aging population of HIV-infected individuals on
ART, it is important to be able to discriminate neurological
impairment caused by HIV itself from other neurocognitive
disorders. CSF biomarkers are of great value in situations like
this, since they can reflect different aspects of the pathogenesis
of HIV CNS infection. CSF neurogranin could, perhaps, in
combination with other CSF biomarkers, contributes to differ-
entiating between HAD and other causes for neurocognitive
decline, for example Alzheimer’s disease [36].
Since HIV does not infect neurons, other mechanisms are
responsible for the synaptodendritic injury, neuronal dysfunc-
tion, and apoptosis that occurs. Although the exact pathogen-
esis remains unclear, some of the key steps in this process
involve viral invasion of the CNS, which triggers local im-
mune activation mediated by infected perivascular macro-
phages and microglia interacting with astrocytes. CSF
neopterin is mainly produced by macrophages and related
cells and is one of the most used markers of cell-mediated
intrathecal immune activation [37, 38]. We found the same
pattern for CSF neopterin levels as in several other studies
[24, 39], with the highest values in those with HAD and there-
after in those with low CD4+ T cell counts. Increased CSF
NFL levels are common in advanced stages of HIV-infection,
particularly in individuals with HAD [24, 40], something we
also found in this study.
This study has several limitations. It has a retrospective
cross-sectional design and even though we did not find any
significant differences in CSF neurogranin levels in the various
Fig. 1 Log concentrations of (a) cerebrospinal fluid (CSF) neurogranin,
(b) CSF neopterin, and (c) CSF NFL for the seven groups of participants:
HIV-negative; NA neuroasymptomatic untreated individuals, subgrouped
by level of blood CD4+ T cell count to CD4 < 50, 50–199, 200–349, and
> 349 T-cells/μL; individuals with diagnosed HAD (HIV-associated
dementia); and individuals on suppressive antiretroviral therapy without
signs of neurological impairment
Fig. 2 Correlation between cerebrospinal fluid (CSF) NFL and CSF
neurogranin with the same color-coding for the seven different groups
of patients as in Fig. 1
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groups of HIV-infected participants, it could be of interest to
follow CSF neurogranin levels in a longitudinal study, especial-
ly after initiation of ART. The total number of participants was
relatively large, but some of the individual groups were limited
in size.
Conclusions
CSF concentrations of neurogranin are increased in
Alzheimer’s disease, but not in other neurodegenerative dis-
order such as Parkinson’s disease, frontotemporal dementia,
Lewy body dementia, progressive supranuclear palsy, or mul-
tiple system atrophy. Our results show that CSF neurogranin
levels are not increased during any stage of HIV-infection
compared to uninfected controls. Since neurogranin is a bio-
marker of synaptic injury, these findings either indicate that
axonal injury occurs in HIV-infected individuals without pre-
ceding synaptic damage or that CSF neurogranin is not sensi-
tive to the type of synaptic impairment that may be present in
HIV-associated neurocognitive disorders.
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